August 2021: BSG Completes Another Successful Executive Search—Vice President of People, Embark Veterinary
Tali Ronen joins Embark Veterinary as an innovative and pragmatic business partner with a proven ability to lead, influence change and execute. She has worked with executive teams and leaders across all functions within biotech. Prior to joining Embark, Tali was Vice President of Human Resources for Lexington Medical, a leading venture-backed medical device manufacturer. She also ran HR for Camp4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gene expression. Before that, Tali spent eight years at Biogen in progressively more senior human resources roles leading to her appointment as HR Country Lead in Canada.
Over the course of her career, Tali has honed her skills in talent strategy, leadership development, talent acquisition, diversity and inclusion, organizational effectiveness, and change management to become a well-rounded leader in her field. She is a graduate of Wellesley College with a degree in Sociology and minor in Economics.
About Embark Veterinary:
Embark Veterinary is considered by many as the world leader in canine genetics. The company has more than doubled in revenue year over year and has landed on the Inc. 5000 fastest-growing companies list the last three years. Launched by two brothers, the company is an official research partner with Cornell University College of Veterinary Medicine and has a mission to end preventable disease in dogs.
Embark offers the most comprehensive dog DNA test on the market. An Embark dog DNA test enables a pet owner to learn about their dog's breed, ancestry, health, and more with a simple cheek swab. The test tracks over 200,000 genetic markers which is more than twice that of any other test on the market. It provides ancestry analysis, as well as an extensive overview of both genetic disease risk and heritable traits. In addition to discovering a dog’s relative risk of conceiving more than 200 medical conditions, owners will learn about dozens of physical traits, like how much a puppy is likely to shed and how big it is likely to grow, as well as breed composition, level of inbreeding, and where their dog's lineage can be traced geographically.
Embark is the only canine genetics company that uses a research-grade DNA genotyping platform to provide its customers with the most accurate results and enable future genetic discoveries. It is the highest-rated test on the market and the world’s only canine relative finder.
Over the past 12 months, Embark has more than doubled sales of its at-home dog DNA test kits and is widely considered to be the best offering available. Backed by F-Prime Capital, Slow Ventures, Section 32, Third Kind Venture Capital, Freestyle Capital, FJ Labs, and Anne Wojciciki, CEO of 23andme, the company expects to rapidly scale its workforce to support growth and drive its mission to improve the life and longevity of all dogs.
For assistance with your next executive search, in the Canine Genomics and Biotechnology sector or across our array of practice area specialties, contact us today.